Aarti Drugs Q1 FY26 Earnings Results

Aarti Drugs Ltd, established in 1984 and part of the $1000 million Aarti Group of Industries, is engaged in manufacturing and selling Active Pharmaceutical Ingredients (APIs), Pharma Intermediates, Specialty Chemicals, as well as pharmaceutical formulations. Presenting below are its Q1 FY26 Earnings Results.

Q1 FY26 Earnings Results

• Revenue: ₹591 crore, up 6.49% year-on-year (YoY) from ₹555 crore in Q1 FY25.
• Total Expenses: ₹540 crore, up 5.47% YoY from ₹512 crore.
• Consolidated Net Profit (PAT): ₹54 crore, up 63.64% from ₹33 crore in the same quarter last year.
• Earnings Per Share (EPS): ₹5.86, up 61.88% from ₹3.62 YoY.

Operational & Strategic Update

• Moderate Revenue Growth: Revenues increased by 6.49%, supported by steady demand across API, intermediates, specialty chemicals, and formulation segments.
• Controlled Expense Growth: Expenses rose by 5.47%, slightly below revenue growth, aiding margin expansion.
• Substantial Profit Increase: Net profit and EPS rose sharply by over 60%, reflecting operational leverage and improved cost efficiencies.
• Market Position: Aarti Drugs Ltd continues to expand its footprint in pharmaceutical and specialty chemical industries with a robust product portfolio and strategic investments.
• Strategic Focus: The company is focused on increasing capacity, improving product mix, and enhancing manufacturing capabilities to drive growth and profitability.

Corporate Developments in Q1 FY26 Earnings

Aarti Drugs Ltd’s Q1 FY26 results underline strong profitability growth driven by revenue traction and disciplined expense management.

Looking Ahead

Aarti Drugs Ltd aims to sustain growth through capacity expansions, new product development, and enhanced downstream integration. Continued investments in innovation and quality are expected to support long-term value creation through FY26 and beyond.

Explore the company’s past earnings and latest concall transcripts, click here to visit the AlphaStreet India News Channel.